Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26475 | 0.92 | ALDH1A1 (0.35) | ALDH1A1LMNACYP1A2TSHRUSP2 | |
| SCHEMBL599081 | 0.91 | ALDH1A1 (0.39) | ALDH1A1LMNACYP1A2TSHRUSP2 | |
| SCHEMBL25774 | 0.87 | ALDH1A1 (0.37) | ALDH1A1LMNACYP1A2TSHRUSP2 | |
| SCHEMBL598614 | 0.86 | ALDH1A1 (0.39) | ALDH1A1LMNACYP1A2TSHRUSP2 | |
| SCHEMBL27369 | 0.86 | ALDH1A1 (0.36) | ALDH1A1LMNACYP1A2TSHRUSP2 | |
| SCHEMBL598388 | 0.85 | ALDH1A1 (0.38) | ALDH1A1LMNACYP1A2TSHRUSP2 | |
| SCHEMBL599115 | 0.85 | SLC18A2 (0.33) | ALDH1A1LMNACYP1A2TSHRUSP2 | |
| SCHEMBL612593 | 0.84 | ALDH1A1 (0.37) | ALDH1A1LMNACYP1A2TSHRUSP2 | |
| SCHEMBL598783 | 0.83 | ALDH1A1 (0.36) | ALDH1A1LMNACYP1A2TSHRUSP2 | |
| SCHEMBL598751 | 0.81 | ALDH1A1 (0.41) | ALDH1A1LMNACYP1A2TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | XENOPORT, INC. | 2008-08-07 | — | — | US | claimed |
| EP-1928450-A2 | TREATING PREMATURE EJACULATION USING GABAPENTIN AND PREGABALIN PRODRUGS | Xenoport, Inc. (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007027476-A2 | TREATING PREMATURE EJACULATION USING GABAPENTIN AND PREGABALIN PRODRUGS | XENOPORT, INC. (US) | 2007-03-08 | — | — | WO | claimed |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | XENOPORT, INC. | 2007-03-01 | — | — | US | claimed |
| US-20070049627-A1 | Treating vulvodynia using prodrugs of GABA analogs | XENOPORT, INC. | 2007-03-01 | — | — | US | claimed |
| US-20120041061-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | XENOPORT INC. | 2012-02-16 | — | — | US | disclosed |
| US-8114909-B2 | Utilizing extended release forms with reduced rates of systemic clearance; eliminating significant side effects | XENOPORT, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100166825-A1 | TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-7700652-B2 | Treating urinary incontinence using prodrugs of GABA analogs | XENOPORT, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090041806-A1 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY | XENOPORT, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080161393-A1 | Use of prodrugs of GABA analogs for treating disease | XENOPORT, INC. | 2008-07-03 | — | — | US | disclosed |
| EP-1928450-A2 | TREATING PREMATURE EJACULATION USING GABAPENTIN AND PREGABALIN PRODRUGS | Xenoport, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007027476-A2 | TREATING PREMATURE EJACULATION USING GABAPENTIN AND PREGABALIN PRODRUGS | XENOPORT, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | XENOPORT, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049627-A1 | Treating vulvodynia using prodrugs of GABA analogs | XENOPORT, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20050209319-A1 | Treatment of local pain | XENOPORT, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050192353-A1 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2005-09-01 | — | — | US | disclosed |
| US-20050090550-A1 | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs | ARBOR PHARMACEUTICALS, LLC | 2005-04-28 | — | — | US | disclosed |
| US-20040254246-A1 | Gabapentin, pregabalin | XENOPORT, INC. | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | GABRB1, GABBR1, GABRB2 | ALDH1A1 148/4885LMNA 3308/4885CYP1A2 648/4885 |
| US-20090041806-A1 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY | GABBR2, GABBR1, GABRB2 | ALDH1A1 2011/4885LMNA 4067/4885CYP1A2 678/4885 |
| US-20120041061-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | GABRB1, GABBR1, GABRB3 | ALDH1A1 2545/4885LMNA 2164/4885CYP1A2 819/4885 |
| US-20040254246-A1 | Gabapentin, pregabalin | GABRB2, GABRB3, GABRB1 | ALDH1A1 780/4885LMNA 3119/4885CYP1A2 252/4885 |
| US-20080161393-A1 | Use of prodrugs of GABA analogs for treating disease | GABRB1, GABBR1, GABRB3 | ALDH1A1 2510/4885LMNA 2191/4885CYP1A2 845/4885 |
| US-20050209319-A1 | Treatment of local pain | GABBR1, GABBR2, GABRB2 | ALDH1A1 1056/4885LMNA 3276/4885CYP1A2 826/4885 |
| US-20070049626-A1 | Treating premature ejaculation using gabapentin and pregabalin prodrugs | GABBR1, GABRE, GABRB2 | ALDH1A1 764/4885LMNA 1408/4885CYP1A2 243/4885 |
| US-20100166825-A1 | TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS | GABBR2, GABRB1, GABBR1 | ALDH1A1 72/4885LMNA 2445/4885CYP1A2 627/4885 |
| US-20070049627-A1 | Treating vulvodynia using prodrugs of GABA analogs | GABBR1, GABBR2, GABRB3 | ALDH1A1 445/4885LMNA 3968/4885CYP1A2 335/4885 |
| US-20050192353-A1 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs | GABRB1, GABBR2, GABARAPL1 | ALDH1A1 1006/4885LMNA 453/4885CYP1A2 370/4885 |
| US-20050090550-A1 | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs | GABBR2, GABRB1, GABBR1 | ALDH1A1 72/4885LMNA 2445/4885CYP1A2 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.